多数据库分析鉴定与肝细胞癌预后相关的关键基因。

Analysis of multiple databases identifies crucial genes correlated with prognosis of hepatocellular carcinoma.

机构信息

Guangdong Province Key Laboratory of Major Obstetric Diseases, Department of Medical Record, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.

Medical Administration Division, Affiliated Huadu Hospital, Southern Medical University (People's Hospiatl of Huadu District), Guangzhou, 510800, China.

出版信息

Sci Rep. 2022 May 30;12(1):9002. doi: 10.1038/s41598-022-13159-4.

DOI:10.1038/s41598-022-13159-4

PMID:35637248

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9151754/

Abstract

Despite advancements made in the therapeutic strategies on hepatocellular carcinoma (HCC), the survival rate of HCC patient is not satisfactory enough. Therefore, there is an urgent need for the valuable prognostic biomarkers in HCC therapy. In this study, we aimed to screen hub genes correlated with prognosis of HCC via multiple databases. 117 HCC-related genes were obtained from the intersection of the four databases. We subsequently identify 10 hub genes (JUN, IL10, CD34, MTOR, PTGS2, PTPRC, SELE, CSF1, APOB, MUC1) from PPI network by Cytoscape software analysis. Significant differential expression of hub genes between HCC tissues and adjacent tissues were observed in UALCAN, HCCDB and HPA databases. These hub genes were significantly associated with immune cell infiltrations and immune checkpoints. The hub genes were correlated with clinical parameters and survival probability of HCC patients. 147 potential targeted therapeutic drugs for HCC were identified through the DGIdb database. These hub genes could be used as novel prognostic biomarkers for HCC therapy.

摘要

尽管在肝细胞癌 (HCC) 的治疗策略上取得了进展，但 HCC 患者的生存率仍不尽如人意。因此，迫切需要有价值的 HCC 治疗预后生物标志物。在这项研究中，我们旨在通过多个数据库筛选与 HCC 预后相关的关键基因。从四个数据库的交集获得了 117 个 HCC 相关基因。随后，我们通过 Cytoscape 软件分析 PPI 网络，确定了 10 个关键基因（JUN、IL10、CD34、MTOR、PTGS2、PTPRC、SELE、CSF1、APOB、MUC1）。在 UALCAN、HCCDB 和 HPA 数据库中观察到 HCC 组织与相邻组织之间关键基因的差异表达具有显著意义。这些关键基因与免疫细胞浸润和免疫检查点显著相关。这些关键基因与 HCC 患者的临床参数和生存概率相关。通过 DGIdb 数据库鉴定了 147 种潜在的 HCC 靶向治疗药物。这些关键基因可作为 HCC 治疗的新型预后生物标志物。